Table 1.
IC50 values of compounds 6a-t, 7 m-t and 8 m-t against two hepatocarcinoma cell lines (SMMC-7721, HepG2 and Hep3B) and normal hepatocyte cell line (QSG-7701).
| Compound | IC50 value (μM) |
|||
|---|---|---|---|---|
| SMMC-7721 | HepG2 | Hep3B | QSG-7701 | |
| 6a | 5.20 ± 0.21 | 2.28 ± 0.19 | 0.82 ± 0.08 | 8.75 ± 0.65 |
| 6b | 13.2 ± 0.76 | 11.7 ± 0.58 | 6.78 ± 0.42 | 27.53 ± 1.87 |
| 6c | 14.00 ± 2.10 | 17.40 ± 1.73 | 10.97 ± 0.65 | 41.05 ± 3.69 |
| 6d | 7.01 ± 0.74 | 5.87 ± 0.42 | 6.31 ± 0.33 | 22.1 ± 2.75 |
| 6e | 17.27 ± 1.78 | 15.65 ± 1.61 | 11.42 ± 0.53 | >50 |
| 6f | >50 | >50 | >50 | NT |
| 6g | >50 | >50 | >50 | NT |
| 6h | >50 | >50 | >50 | NT |
| 7a | 5.10 ± 0.18 | 3.10 ± 0.45 | 1.37 ± 0.20 | 17.22 ± 1.89 |
| 7b | 6.80 ± 0.72 | 29.00 ± 1.29 | 5.98 ± 0.39 | >50 |
| 7c | >50 | >50 | 40.72 ± 2.62 | NT |
| 7d | 10.34 ± 1.02 | 8.68 ± 1.13 | 12.83 ± 0.67 | 32.79 ± 3.22 |
| 7e | 23.34 ± 2.35 | 16.85 ± 1.58 | 20.03 ± 1.22 | >50 |
| 7f | >50 | >50 | >50 | NT |
| 7g | >50 | >50 | >50 | NT |
| 7h | >50 | >50 | >50 | NT |
| 8a | 6.10 ± 0.47 | 4.80 ± 0.32 | 2.89 ± 0.27 | 23.38 ± 2.97 |
| 8b | 34.90 ± 3.35 | 19.60 ± 2.91 | 18.34 ± 1.02 | >50 |
| 8c | >50 | >50 | >50 | NT |
| 8d | 12.77 ± 0.84 | 11.52 ± 1.23 | 14.38 ± 0.77 | 43.65 ± 4.03 |
| 8e | 32.12 ± 2.78 | 41.17 ± 3.56 | 38.02 ± 1.75 | >50 |
| 8f | >50 | >50 | >50 | NT |
| 8g | >50 | >50 | >50 | NT |
| 8h | >50 | >50 | >50 | NT |
| Doxorubicin | 1.13 ± 0.11 | 2.38 ± 0.29 | 1.02 ± 0.09 | 13.78 ± 0.53 |
The results are expressed as mean value ± SD.
NT: Not tested.